Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2014 06:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function Comparability to ERT Also Demonstrated in...
August 07, 2014 16:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates

Results From Second Phase 3 Fabry Monotherapy Study (Study 012) on Track for 3Q14 Updated Preclinical Data for Next-Generation Pompe ERT Shows Superior Substrate Reduction Compared to Current...
July 31, 2014 16:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014

CRANBURY, N.J., July 31, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, August 7, 2014 at 5:00 p.m. ET to discuss...
June 30, 2014 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q14 96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension...
May 14, 2014 16:08 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at UBS Global Healthcare Conference

CRANBURY, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...
May 05, 2014 16:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces First Quarter 2014 Financial Results and Corporate Updates

Positive 12- and 24-Month Data From First Phase 3 Fabry Monotherapy Study (Study 011) – Results from Second Phase 3 Fabry Monotherapy Study (Study 012) Expected 3Q14 3-in-3 Strategy to...
April 29, 2014 06:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Positive 12- and 24-Month Data From Phase 3 Fabry Monotherapy Study 011

Migalastat Demonstrated Statistically Significant (p=0.013) and Durable Substrate Reductions on 12-Month Pre-Specified Primary Analysis in Fabry Patients with Amenable Mutations Statistically...
March 27, 2014 16:38 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at 13th Annual Needham Healthcare Conference

CRANBURY, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...
March 03, 2014 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Full-Year 2013 Financial Results and Corporate Updates

Executing 3-in-3 Strategy to Advance 3 Next-Generation ERTs into Clinic in Next 3 Years Reiterating FY14 Cash Spend Guidance of $54-$59 Million CRANBURY, N.J., March 3, 2014 (GLOBE NEWSWIRE) --...
March 03, 2014 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and Promotes Bradley L. Campbell to Chief Operating Officer

CRANBURY, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the...